{"filing":{"accession_number":"0001213900-26-082584","cik":"0001611746","ticker":"SPRC","company_name":"SciSparc Ltd.","form":"6-K","filing_date":"2026-07-29","report_date":"2026-07-29","primary_document":"ea0299645-6k_scisparc.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1611746/000121390026082584/ea0299645-6k_scisparc.htm"},"events":[{"id":21489,"run_id":19382,"accession_number":"0001213900-26-082584","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"summary":"SciSparc's board announced a strategic decision to target the agentic AI market and establish a Scientific Advisory Board for AI and cybersecurity, representing a material shift in the company's business focus and strategic direction.","company_name":"SciSparc Ltd.","ticker":"SPRC","filing_date":"2026-07-29","form":"6-K","submitted_at":null,"items":[{"id":21143,"accession_number":"0001213900-26-082584","item_number":"EX-99.1","item_title":"ea029964501ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"SciSparc announces a strategic decision by its board to target the agentic AI market and establish a Scientific Advisory Board for AI and cybersecurity, representing a material shift in the company's business focus and strategic direction. While the company is currently in the evaluation and discussion phase rather than having completed a specific transaction or appointment, the board's decision to pivot toward a new market segment and the formation of a new advisory board constitute a material operational and strategic event that would affect a reasonable investor's assessment of the company's future direction and resource allocation.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-29T13:12:41.506770+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":21490,"run_id":19382,"accession_number":"0001213900-26-082584","anchor_item_number":"EX-99.2","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"summary":"NeuroThera Labs, SciSparc's majority-owned subsidiary, completed internal validation of its proprietary quantum computing platform (CliniQuantum) for clinical data analytics, demonstrating successful validation of a quantum sampling workflow on a hybrid quantum-classical platform with potential applications to drug development and clinical trials.","company_name":"SciSparc Ltd.","ticker":"SPRC","filing_date":"2026-07-29","form":"6-K","submitted_at":null,"items":[{"id":21144,"accession_number":"0001213900-26-082584","item_number":"EX-99.2","item_title":"ea029964501ex99-2.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"This press release announces that NeuroThera Labs (SciSparc's majority-owned subsidiary) has completed internal validation of a proprietary quantum computing platform for clinical data analytics. The disclosure describes a technological milestone—successful validation of a quantum sampling workflow on an S\u0026P 500 company's hybrid quantum-classical platform—and its potential application to drug development and clinical trials. While the announcement emphasizes the platform's capabilities and future potential, it does not disclose a discrete operational event (like a partnership, contract, or restructuring) that would fit a more specific category. The validation is a development milestone for an existing technology initiative (CliniQuantum) rather than a new material contract or strategic partnership announcement. This is best classified as an operational/strategic technology advancement that would be material to investors assessing the company's innovation pipeline and subsidiary capabilities.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-29T13:12:41.506770+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21143,"accession_number":"0001213900-26-082584","item_number":"EX-99.1","item_title":"ea029964501ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"SciSparc announces a strategic decision by its board to target the agentic AI market and establish a Scientific Advisory Board for AI and cybersecurity, representing a material shift in the company's business focus and strategic direction. While the company is currently in the evaluation and discussion phase rather than having completed a specific transaction or appointment, the board's decision to pivot toward a new market segment and the formation of a new advisory board constitute a material operational and strategic event that would affect a reasonable investor's assessment of the company's future direction and resource allocation.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-29T13:12:41.506770+00:00","company_name":"SciSparc Ltd.","ticker":"SPRC","filing_date":"2026-07-29"},{"id":21144,"accession_number":"0001213900-26-082584","item_number":"EX-99.2","item_title":"ea029964501ex99-2.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"This press release announces that NeuroThera Labs (SciSparc's majority-owned subsidiary) has completed internal validation of a proprietary quantum computing platform for clinical data analytics. The disclosure describes a technological milestone—successful validation of a quantum sampling workflow on an S\u0026P 500 company's hybrid quantum-classical platform—and its potential application to drug development and clinical trials. While the announcement emphasizes the platform's capabilities and future potential, it does not disclose a discrete operational event (like a partnership, contract, or restructuring) that would fit a more specific category. The validation is a development milestone for an existing technology initiative (CliniQuantum) rather than a new material contract or strategic partnership announcement. This is best classified as an operational/strategic technology advancement that would be material to investors assessing the company's innovation pipeline and subsidiary capabilities.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-29T13:12:41.506770+00:00","company_name":"SciSparc Ltd.","ticker":"SPRC","filing_date":"2026-07-29"}]}